This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and 1.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q1 Earnings Meet Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 0% and 3.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 2.33% and 2.28%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q4 Earnings Match Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 0% and 0.71%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Otter Tail, OraSure, BioMarin and Regeneron
by Zacks Equity Research
Otter Tail, OraSure, BioMarin and Regeneron have been highlighted in this Screen of The Week article.
Buy These 4 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.
After Golden Cross, OraSure Technologies (OSUR)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OraSure Technologies (OSUR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 285.71% and 19.36%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -16.67% and 32.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 131.25% and 21.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?
by Zacks Equity Research
OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Zacks.com featured highlights include OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop
by Zacks Equity Research
OraSure Technologies, Compania de Minas Buenaventura SAA and Vipshop are part of the Zacks Screen of the Week article.
3 Low-Beta Stocks to Buy to Combat the Volatile Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa??ia de Minas (BVN) and Vipshop Holdings (VIPS) are poised to gain.
Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock
by Zacks Equity Research
OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 216.67% and 26.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Break-Even Earnings for Q2
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 100% and 13.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 67.57% and 2.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -320.00% and 13.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for OraSure Technologies (OSUR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OraSure Technologies (OSUR) stock based on the movements in the options market lately.